Breaking News

AtheroNova, Frontage in Clinical Trial Supply Pact

Frontage to provide analysis, formulation and validation for AHRO-001 tablets

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AtheroNova has signed an agreement with Frontage Laboratories to begin work on the formulation, compounding and tableting of AHRO-001 for Phase I studies. Frontage will immediately commence work on the analysis, formulation and validation of the various processes and procedures for manufacturing AHRO-001 tablets for AtheroNova. “Frontage has been extremely diligent in dealing with the technical and physical requirements of our AHRO-001 compound and we look forward to commencing our project in t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters